Crosswalk Therapeutics

Crosswalk Therapeutics is pleased to share our plans to develop a novel, next-generation enzyme replacement therapy (ERT) for Fabry disease. Our discussions with physicians and patients at this year’s WORLDSymposium, MPS Society UK, here for those with rare diseases Fabry Matters conference, and the 8th Update on Fabry Disease event from @Kidneys for Life have further illuminated for us the unmet need in the patient community and the transformative potential of our investigational technology to improve the lives of people living with Fabry disease. Natalia Boukharov, our Head of Nonclinical Research, and John Chapin, our Head of Clinical Research, presented a poster at the 8th Update on Fabry Disease Conference in Hamburg, Germany. The aim of the poster presentation, “An analysis of clinical endpoints and industry-sponsored drug development in Fabry disease,” was to foster a conversation on the challenges of designing Fabry clinical trials. Crosswalk received invaluable feedback and insights from experts. It established new connections that will help facilitate the development of our novel investigational ERT to address the current unmet needs of Fabry patients. "Patients with Fabry disease have had marked improvement in the quality of their lives with the availability of enzyme replacement therapies and more recently chaperone therapy. It is very exciting for these patients, and their treaters, to see the second generation of therapies being developed. The current unmet clinical needs of these patients include the development of anti-drug antibodies, and tissue distribution and efficacy, especially for the cardiomyocytes. The present development efforts are directly targeting these issues and may well usher in an exciting new chapter in the treatment of Fabry disease."- David Warnock, MD, Professor of Medicine (Emeritus), University of Alabama at Birmingham. We are so excited to continue our momentum. Everyone at Crosswalk remains dedicated to the Fabry patient community (patients, caregivers, and loved ones) and we will continue to work tirelessly to develop technology and therapies intended to offer new hope and new options. Learn more about the exciting work we’re doing: https://lnkd.in/eXw_HBAK #raredisease #drugdevelopment #startup #lifesciences #biotech #healthinnovation #fabrydisease #healthcare #pharmaceuticals #healthtechnology #ERT #enzymereplacementtherapy

Crosswalk Therapeutics announces acquisition of rare disease assets from Codexis, Inc. https://lnkd.in/es6wnWKg 

Introducing Crosswalk Therapeutics, formerly Zebra Biopharma. What better time to unveil our rebranding initiative for a rare disease company than on Rare Disease Day, when our community rallies together in an awareness campaign known as "Show Your Stripes." Today, we proudly unveil our new identity, transitioning from Zebra Biopharma to Crosswalk Therapeutics.   Why the change from Zebra? When we envisioned our company's future, our mission was clear – eliminate rare diseases. When we opened our doors to create biopharmaceutical solutions for our patients, we chose the zebra as a fitting guiding symbol for our work. Zebras have become emblematic in the rare disease community, representing the uniqueness and challenges faced by those with rare conditions. However, as our budding startup emerged, it was clear that we needed a brand that more fully captures the complexity of not only the experience of our patients but also includes a forward-looking focus on life beyond a cure. Our goal goes beyond developing medicines. We strive to provide a path forward that includes a real and lasting quality of life. We're building a bridge to hope for families, not just treatments.   Why are we now called Crosswalk Therapeutics? Our crosswalk goes beyond stripes. It's about parents guiding their children safely across busy and often confusing streets of medical care. It symbolizes progress and protection. It's about how a fiercely dedicated team of scientists strive to provide a safe passage from one part of a difficult and painful journey to what’s possible on the other side.   As we work to communicate the goals of our work to investors and scientific colleagues outside of rare diseases, we want to be crystal clear about the breadth of our mission. Our journey is not limited to developing therapies; it's also about educating the public and shining a light on the needs of our patients and the life-changing medicines we can provide.   We hope you’ll join us in our excitement to rebrand to communicate our mission more fully. The team at Crosswalk Therapeutics believes this change will help us tell our story more completely for our investors and colleagues who will partner with us in the effort to eradicate rare diseases – work we know will truly impact the lives of real people.

Introducing Crosswalk Therapeutics, formerly Zebra Biopharma. What better time to unveil our rebranding initiative for a rare disease company than on Rare Disease Day, when our community rallies together in an awareness campaign known as "Show Your Stripes." Today, we proudly unveil our new identity, transitioning from Zebra Biopharma to Crosswalk Therapeutics.   Why the change from Zebra? When we envisioned our company's future, our mission was clear – eliminate rare diseases. When we opened our doors to create biopharmaceutical solutions for our patients, we chose the zebra as a fitting guiding symbol for our work. Zebras have become emblematic in the rare disease community, representing the uniqueness and challenges faced by those with rare conditions. However, as our budding startup emerged, it was clear that we needed a brand that more fully captures the complexity of not only the experience of our patients but also includes a forward-looking focus on life beyond a cure. Our goal goes beyond developing medicines. We strive to provide a path forward that includes a real and lasting quality of life. We're building a bridge to hope for families, not just treatments.   Why are we now called Crosswalk Therapeutics? Our crosswalk goes beyond stripes. It's about parents guiding their children safely across busy and often confusing streets of medical care. It symbolizes progress and protection. It's about how a fiercely dedicated team of scientists strive to provide a safe passage from one part of a difficult and painful journey to what’s possible on the other side.   As we work to communicate the goals of our work to investors and scientific colleagues outside of rare diseases, we want to be crystal clear about the breadth of our mission. Our journey is not limited to developing therapies; it's also about educating the public and shining a light on the needs of our patients and the life-changing medicines we can provide.   We hope you’ll join us in our excitement to rebrand to communicate our mission more fully. The team at Crosswalk Therapeutics believes this change will help us tell our story more completely for our investors and colleagues who will partner with us in the effort to eradicate rare diseases – work we know will truly impact the lives of real people.

Introducing Crosswalk Therapeutics, formerly Zebra Biopharma. What better time to unveil our rebranding initiative for a rare disease company than on Rare Disease Day, when our community rallies together in an awareness campaign known as "Show Your Stripes." Today, we proudly unveil our new identity, transitioning from Zebra Biopharma to Crosswalk Therapeutics.   Why the change from Zebra? When we envisioned our company's future, our mission was clear – eliminate rare diseases. When we opened our doors to create biopharmaceutical solutions for our patients, we chose the zebra as a fitting guiding symbol for our work. Zebras have become emblematic in the rare disease community, representing the uniqueness and challenges faced by those with rare conditions. However, as our budding startup emerged, it was clear that we needed a brand that more fully captures the complexity of not only the experience of our patients but also includes a forward-looking focus on life beyond a cure. Our goal goes beyond developing medicines. We strive to provide a path forward that includes a real and lasting quality of life. We're building a bridge to hope for families, not just treatments.   Why are we now called Crosswalk Therapeutics? Our crosswalk goes beyond stripes. It's about parents guiding their children safely across busy and often confusing streets of medical care. It symbolizes progress and protection. It's about how a fiercely dedicated team of scientists strive to provide a safe passage from one part of a difficult and painful journey to what’s possible on the other side.   As we work to communicate the goals of our work to investors and scientific colleagues outside of rare diseases, we want to be crystal clear about the breadth of our mission. Our journey is not limited to developing therapies; it's also about educating the public and shining a light on the needs of our patients and the life-changing medicines we can provide.   We hope you’ll join us in our excitement to rebrand to communicate our mission more fully. The team at Crosswalk Therapeutics believes this change will help us tell our story more completely for our investors and colleagues who will partner with us in the effort to eradicate rare diseases – work we know will truly impact the lives of real people.